KYDES products are developed from currently approved drug compounds and FDA approved excipients using our proprietary technologies. The products will be manufactured to meet or exceed Current Good Manufacturing Practices (CGMP) Guidelines set forth by the FDA and other Regulatory Agencies. The products listed in the menu above are in various stages of development.
Click on the products below for details.
|KY1101 & KY1102||KY1103||KY1104||KY1105||KY1106||KY1107|
KY003 is being developed for the treatment of malignant and non-malignant, proliferative gynecological disorders such as cervical, vaginal, uterine cancers, heavy menstrual bleeding, adenomyosis, endometriosis, cervical dysplasia and fibroids.
Pelvic malignancies are significant cause of mortality and morbidity in women. Almost 15% of all cancers in women are invasive neoplasm of the female pelvic organs. In 2004, approximately 82,550 women in the United States were predicted to receive a diagnosis of pelvic gynecologic malignancy. The most common of these malignancies is uterine cancer, specifically, endometrial cancer which is the fourth most common cancer in women with 40,320 cases predicted for 2004 and 7090 deaths. Ovarian cancer accounts for the largest number of cancer deaths from pelvic gynecologic malignancies, with 23,100 new cases and 14,000 deaths predicted for 2000. Other pelvic malignancies include cervical cancer, bladder cancer, rectal cancer and vaginal cancer. In addition to these malignant tumors, there are other pelvic benign tumors with significant morbidity. These include endometriosis, adenomyosis, uterine leiomyomata (fibroids), menorrhagia, endometrial hyperplasia and uterine polyps. Taken together, malignant and non-malignant pathologies of the pelvis affect more than 50% of all women above the age of 30.
KYDES is developing locally intensive therapies for the treatment of benign and malignant gynecological disorders.